Prognostic role of pathologic status other than complete response after neoadjuvant therapy followed by surgery in esophageal squamous cell carcinoma

• Published in: Esophagus : official journal of the Japan Esophageal Society 2024-01, Vol.21 (1), p.51-57
• Main Authors: Park, Seong Yong, Lee, Junghee, Oh, Dongryul, Sun, Jong-Mu, Yun, Jeonghee, Jeon, Yeong Jeong, Cho, Jong Ho, Choi, Yong Soo, Zo, Jae Il, Shim, Young Mog, Kim, Hong Kwan
• Format: Article
• Language: English
• Subjects: Cancer surgery; Cancer therapies; Chemotherapy; Clinical outcomes; Esophageal cancer; Gastroenterology; Medical prognosis; Medicine; Medicine & Public Health; Original Article; Pathology; Squamous cell carcinoma; Surgical Oncology; Thoracic Surgery
• ISSN: 1612-9059; 1612-9067
• DOI: 10.1007/s10388-023-01031-x

Background This retrospective study was performed to investigate the survival differences according to the pathologic status after neoadjuvant chemotherapy followed by surgery in esophageal squamous cell carcinoma (ESCC), and to investigate whether current AJCC 8th ypStage can predict survival accurately. Methods Data of 563 patients who received neoadjuvant therapy and esophagectomy for ESCC between 1994 and 2018 were retrospectively reviewed. Results The mean age was 62.00 ± 8.01 years, of which 524 (93.1%) were males. The median follow-up period was 29.12 months. A total of 153 (27.1%) patients showed pathologic complete response (pCR) and 92 (16.3%) patients showed pCR of the primary lesion with residual metastatic lymph nodes (ypT0N +). A total of 196 (35%) and 122 (21.6%) patients showed ypT + N + and ypT + N, respectively. The 5-year overall survival (OS) of each group was 75.1% (CR), 42.4% (ypT + N0), 54.9% (ypT0N +), and 26.1% (ypT + N +); CR patients showed better survival than the other groups, and no survival differences were found in the 5-year OS between ypT + N0 and ypT0N + patients (p = 0.811). In ypStage I, there were survival differences between ypT0N0 and ypTis-2N0 patients, and ypT1N0 (ypStage I) and ypT0N1 (ypStageIIIA) showed similar OS (5-year OS in 49.3% vs. 67.1%, p = 0.623). Conclusions pCR offers long-term survival in patients; however, survival significantly declines with the presence of residual primary lesion and nodal metastases.